NCT04987320View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Olpasiran in Chinese Participants With Elevated Serum Lipoprotein(a)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 28, 2021

Primary Completion Date

November 12, 2021

Study Completion Date

March 18, 2022

Conditions
Elevated Serum Lipoprotein(a)
Interventions
DRUG

Olpasiran

Subcutaneous injection

Trial Locations (1)

Unknown

Queen Mary Hospital, Hong Kong

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT04987320 - A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Olpasiran in Chinese Participants With Elevated Serum Lipoprotein(a) | Biotech Hunter | Biotech Hunter